Limits...
A dermocosmetic containing bakuchiol, Ginkgo biloba extract and mannitol improves the efficacy of adapalene in patients with acne vulgaris: result from a controlled randomized trial.

Poláková K, Fauger A, Sayag M, Jourdan E - Clin Cosmet Investig Dermatol (2015)

Bottom Line: Quality of life had improved more with the active combination than with the vehicle combination.In the active group, four subjects had to interrupt temporarily BGM complex and 12 adapalene compared to seven subjects interrupting the vehicle and eleven adapalene in the vehicle group.Overall, safety and local tolerance of BGM complex were good.

View Article: PubMed Central - PubMed

Affiliation: Saint elisabeth´s Oncological Institute, Bratislava, Slovakia.

ABSTRACT

Background: Acne vulgaris is an inflammatory disorder of the pilosebaceous unit.

Aim: To confirm that BGM (bakuchiol, Ginkgo biloba extract, and mannitol) complex increases the established clinical efficacy of adapalene 0.1% gel in patients with acne.

Methods: A clinical trial was conducted in acne patients. A total of 111 subjects received adapalene 0.1% gel and BGM complex or vehicle cream for 2 months. Assessments comprised Investigator Global Assessment (IGA), global efficacy, seborrhea intensity, inflammatory and non-inflammatory lesions, and subject perception, as well as overall safety and local tolerance and quality of life.

Results: At the end of the trial, inflammatory and non-inflammatory lesions, IGA, global efficacy, and seborrhea intensity had significantly improved in both treatment groups. Differences were statistically significant (P<0.05) in favor of BGM complex for inflammatory lesions as well as IGA and seborrhea intensity. Global efficacy assessments and subject perception confirmed the superiority of BGM complex-including treatment over the comparative combination. Quality of life had improved more with the active combination than with the vehicle combination. In the active group, four subjects had to interrupt temporarily BGM complex and 12 adapalene compared to seven subjects interrupting the vehicle and eleven adapalene in the vehicle group. One subject withdrew from the trial due to an allergy to adapalene. The majority of all events were mild.

Conclusion: BGM complex improves the treatment outcome of adapalene 0.1% gel in patients with acne vulgaris. Overall, safety and local tolerance of BGM complex were good.

No MeSH data available.


Related in: MedlinePlus

Percent decrease over time of acne lesions: (A) non-inflammatory and (B) inflammatory lesions.Notes: At D56, the difference to D0 was statistically significant (P<0.005) for both groups. The between-treatment group difference was not significant for non-inflammatory lesions, while it was significant for inflammatory lesions (P<0.05).Abbreviation: D, day.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401329&req=5

f1-ccid-8-187: Percent decrease over time of acne lesions: (A) non-inflammatory and (B) inflammatory lesions.Notes: At D56, the difference to D0 was statistically significant (P<0.005) for both groups. The between-treatment group difference was not significant for non-inflammatory lesions, while it was significant for inflammatory lesions (P<0.05).Abbreviation: D, day.

Mentions: After 56 days of treatment, the mean number of non-inflammatory lesions had decreased from 34.4±23.5 to 15.2±13.5 lesions in the active association group and from 29.3±20.3 to 14.6±8.5 lesions in the vehicle association group. The percent decrease at D56 from D0 reached 56% and 50.2% in the active association and the vehicle association groups, respectively (Figure 1A). These reductions were statistically significant (P<0.005) for each group and sustained from D28. The difference between both groups was not statistically significant.


A dermocosmetic containing bakuchiol, Ginkgo biloba extract and mannitol improves the efficacy of adapalene in patients with acne vulgaris: result from a controlled randomized trial.

Poláková K, Fauger A, Sayag M, Jourdan E - Clin Cosmet Investig Dermatol (2015)

Percent decrease over time of acne lesions: (A) non-inflammatory and (B) inflammatory lesions.Notes: At D56, the difference to D0 was statistically significant (P<0.005) for both groups. The between-treatment group difference was not significant for non-inflammatory lesions, while it was significant for inflammatory lesions (P<0.05).Abbreviation: D, day.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401329&req=5

f1-ccid-8-187: Percent decrease over time of acne lesions: (A) non-inflammatory and (B) inflammatory lesions.Notes: At D56, the difference to D0 was statistically significant (P<0.005) for both groups. The between-treatment group difference was not significant for non-inflammatory lesions, while it was significant for inflammatory lesions (P<0.05).Abbreviation: D, day.
Mentions: After 56 days of treatment, the mean number of non-inflammatory lesions had decreased from 34.4±23.5 to 15.2±13.5 lesions in the active association group and from 29.3±20.3 to 14.6±8.5 lesions in the vehicle association group. The percent decrease at D56 from D0 reached 56% and 50.2% in the active association and the vehicle association groups, respectively (Figure 1A). These reductions were statistically significant (P<0.005) for each group and sustained from D28. The difference between both groups was not statistically significant.

Bottom Line: Quality of life had improved more with the active combination than with the vehicle combination.In the active group, four subjects had to interrupt temporarily BGM complex and 12 adapalene compared to seven subjects interrupting the vehicle and eleven adapalene in the vehicle group.Overall, safety and local tolerance of BGM complex were good.

View Article: PubMed Central - PubMed

Affiliation: Saint elisabeth´s Oncological Institute, Bratislava, Slovakia.

ABSTRACT

Background: Acne vulgaris is an inflammatory disorder of the pilosebaceous unit.

Aim: To confirm that BGM (bakuchiol, Ginkgo biloba extract, and mannitol) complex increases the established clinical efficacy of adapalene 0.1% gel in patients with acne.

Methods: A clinical trial was conducted in acne patients. A total of 111 subjects received adapalene 0.1% gel and BGM complex or vehicle cream for 2 months. Assessments comprised Investigator Global Assessment (IGA), global efficacy, seborrhea intensity, inflammatory and non-inflammatory lesions, and subject perception, as well as overall safety and local tolerance and quality of life.

Results: At the end of the trial, inflammatory and non-inflammatory lesions, IGA, global efficacy, and seborrhea intensity had significantly improved in both treatment groups. Differences were statistically significant (P<0.05) in favor of BGM complex for inflammatory lesions as well as IGA and seborrhea intensity. Global efficacy assessments and subject perception confirmed the superiority of BGM complex-including treatment over the comparative combination. Quality of life had improved more with the active combination than with the vehicle combination. In the active group, four subjects had to interrupt temporarily BGM complex and 12 adapalene compared to seven subjects interrupting the vehicle and eleven adapalene in the vehicle group. One subject withdrew from the trial due to an allergy to adapalene. The majority of all events were mild.

Conclusion: BGM complex improves the treatment outcome of adapalene 0.1% gel in patients with acne vulgaris. Overall, safety and local tolerance of BGM complex were good.

No MeSH data available.


Related in: MedlinePlus